SAN DIEGO, Nov. 4, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against TreeHouse Foods, Inc., Zimmer Biomet Holdings, Inc., AAC Holdings, Inc. and Big Lots Inc., as detailed below:
TreeHouse Foods, Inc. Johnson & Weaver, LLP is investigating potential violations of federal and state laws by certain officers and directors of TreeHouse Foods, Inc. (NYSE: THS). On November 3, 2016, TreeHouse reported a third-quarter profit of $37.2 million or 65 cents per share. Earnings, adjusted for one-time gains and costs, came to 70 cents per share. These results did not meet Wall Street expectations as the average estimate of nine analysts was 77 cents per share. TreeHouse posted revenue of $1.59 billion in the period, also missing forecasts. Additionally, TreeHouse announced the closure of a plant in Delta, British Columbia, that it was reducing the workforce at its facility in Battle Creek, Michigan and the resignation of its President and the appointment of a new CFO. On the news, the stock price of TreeHouse dropped over 19% on November 3, 2016. If you have information that could assist in this investigation, including past employees and others, or if you are a TreeHouse shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ( firstname.lastname@example.org) by email or phone at 619-814-4471. If emailing, please include a phone number where you can be reached. Zimmer Biomet Holdings, Inc. Johnson & Weaver, LLP is investigating potential violations of federal and state laws by certain officers and directors of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ). On October 31, 2016, Zimmer announced that it was reducing its full-year forecast for 2016 from a previous estimate of $7.71 billion; Zimmer now predicts revenues to be between $7.63 billion and $7.65 billion. On the news, Zimmer shares closed down 14% on October 31, 2016. On a conference call after the announcement the Company said it was not able to supply enough hip and knee replacements. The supply shortfall caused orthopedic surgeons to source other brands of joint replacement products.